Posted in | News

Abakan to Construct Production Facility in Euclid, Ohio

MesoCoat, a subsidiary of Abakan, a Miami-based company, has declared the construction commencement of its new 11,000 sq. ft production facility in Euclid, Ohio, with an investment of $6-million.

The proposed plant will provide enough space to test, produce and commercialize a range of its new products. Abakan will utilize the space to test and develop its portfolio of wear resistant and anti-corrosion coatings.

The new plant will incorporate a CermaClad manufacturing line to produce up to 10,000 square meters of rust and wear-resistant clad pipes, tubes and plates every year. The CermaClad products considerably increase the robustness and life period of the components that are utilized in a range of vital applications such as nuclear power generation and deep-sea oil wells. The proposed plant will have the latest blasting, application and checking equipment to manufacture products with the advanced type of coating. The plant also will incorporate a thermal spray system to market Mesocoat’s PComP group of products and make them suitable for use in the oil and gas, aerospace, chemical processing and mining industries.

The ground work for the Euclid Plant  started on 7th April 2011 and the company is looking forward to completing the construction of the building by August 2011, and install the required production equipment in the subsequent two months to enable full-scale production at the plant by the end of 2011. MesoCoat also has made arrangements to double the size of the plant largely by constructing an additional 30,000 sq. ft. space for its research and development facility.

Source: http://www.abakaninc.com/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 22). Abakan to Construct Production Facility in Euclid, Ohio. AZoBuild. Retrieved on November 22, 2024 from https://www.azobuild.com/news.aspx?newsID=13812.

  • MLA

    Scanlon, Joel. "Abakan to Construct Production Facility in Euclid, Ohio". AZoBuild. 22 November 2024. <https://www.azobuild.com/news.aspx?newsID=13812>.

  • Chicago

    Scanlon, Joel. "Abakan to Construct Production Facility in Euclid, Ohio". AZoBuild. https://www.azobuild.com/news.aspx?newsID=13812. (accessed November 22, 2024).

  • Harvard

    Scanlon, Joel. 2019. Abakan to Construct Production Facility in Euclid, Ohio. AZoBuild, viewed 22 November 2024, https://www.azobuild.com/news.aspx?newsID=13812.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.